The administration of an engineered fusion form of the chemokine CCL4 targeting the tumor stroma enhances both DCs and T cell immune infiltration and markedly boosts the responsiveness to ICB in poorly T-cell-infiltrated tumors (cold tumor) [61]. This evidence concerns the gene CCL4 and neoplasm.